OncRef

Clinical Trial: NCT03703297

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2025-11-21

Study Overview

Brief Summary

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Official Title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Conditions

Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Durvalumab
  • Drug: Tremelimumab
  • Other: Placebo

Other Study ID Numbers

  • D933QC00001
  • 2018-000867-10
  • 2018

Start Date (Actual)

2018-09-27

Primary Completion Date (Actual)

2024-01-15

Study Completion Date (Estimated)

2026-10-23

Enrollment (Actual)

730

Study Type

Interventional

Phase

Phase 3